GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (OTCPK:SNPHY) » Definitions » Net Income (Discontinued Operations)

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Net Income (Discontinued Operations) : $0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Santen Pharmaceutical Co Net Income (Discontinued Operations)?

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods. Santen Pharmaceutical Co's Net Income (Discontinued Operations) for the three months ended in Dec. 2023 was $0 Mil. Its Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Dec. 2023 was $0 Mil.


Santen Pharmaceutical Co Net Income (Discontinued Operations) Historical Data

The historical data trend for Santen Pharmaceutical Co's Net Income (Discontinued Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santen Pharmaceutical Co Net Income (Discontinued Operations) Chart

Santen Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Net Income (Discontinued Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Santen Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income (Discontinued Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Santen Pharmaceutical Co Net Income (Discontinued Operations) Calculation

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods.

Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Santen Pharmaceutical Co Net Income (Discontinued Operations) Related Terms

Thank you for viewing the detailed overview of Santen Pharmaceutical Co's Net Income (Discontinued Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


Santen Pharmaceutical Co (Santen Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Headlines

From GuruFocus

Matthews Japan Fund Comments on Santen Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood 04-23-2020

Matthews Japan Fund 1st-Quarter Commentary

By Sydnee Gatewood Sydnee Gatewood 04-23-2020